Houston, TX, (April 5, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announced that it is being covered by JM Dutton & Associates. The report can be found by visiting JM Dutton at www.jmdutton.com. Dr. William R. Prather, JM Dutton's senior healthcare market analyst authored this independent analysis of the Company.
Dr. Prather concludes, "At current levels, the Company remains an unexploited, virtually undiscovered company with exciting new technology. Our rating for CytoGenix shares is a Speculative Buy with a 12-month price target of $0.90."
Lawrence Wunderlich, Cytogenix Chief Financial Officer commented, "We are encouraged by Dr. Prather's findings. Although in our opinion, they are somewhat conservative. We both agree that the Company is significantly undervalued by the market. The true value of a biopharmaceutical company is reflected in its pipeline. Our product pipeline is solid proof that our products address very large markets and that we continue to add value." added Mr. Wunderlich.
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 44 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (407) 774-9949
